Sometimes, it’s hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ:SAVA). As the ...

Last year, Cassava Sciences (Nasdaq: SAVA) led the market as it swiftly progressed through clinical trials. But, with SAVA stock down over 68% from its highs, is it a good time to buy? Cassava is a ...

The Alzheimer’s drug market climbed to a value of $6.34 billion in 2020, according to research company IMARC, and there are various pharmaceutical firms with Alzheimer’s drugs in their pipelines. One ...

Given the potential, tremendous benefits of Cassava’s Alzheimer’s drug for millions of patients and the high probability of the drug being approved, I believe that Cassava Sciences (NASDAQ:SAVA) stock ...

Clinical-stage biotech company Cassava (NASDAQ:SAVA) has a lot to write home about today. SAVA stock closed up nearly 20% after a new article attempted to clear its name of troubling accusations.

Companies seeking approval for drugs treating Alzheimer’s disease have tended to be among the stocks biotech investors watched but didn’t hold much hope for. That’s because prior to the Food and Drug ...